News
WILMINGTON, Del., November 25, 2024--Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback